The Inevitable Horizon: Understanding Loss of Exclusivity (LOE) The pharmaceutical landscape is characterized by cycles of innovation, market exclusivity, and […]

1. The Stakes: What a Failed 351(k) Filing Actually Costs A Complete Response Letter (CRL) is not an administrative inconvenience.

1. Why Traditional Drug R&D Is Structurally Broken Between 2000 and 2015, more than 86% of drug candidates that entered

An authorized generic is a brand-name drug sold under a generic label. No new FDA approval required. No new manufacturing

The gap between how small-molecule and biologic patents perform at the Patent Trial and Appeal Board has never been wider,

Pharmaceutical pay-for-delay agreements, the precise term is reverse payment patent settlements, sit at the intersection of Hatch-Waxman exclusivity mechanics, branded

Section 1: What an Authorized Generic Actually Is (And Why Definitions Matter for Deal Modeling) 1.1 The Core Definition An

For IP teams, portfolio managers, R&D leads, and institutional investors who need more than an overview. A pharmaceutical patent is